uniQure (NASDAQ:QURE) Price Target Lowered to $9.00 at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its target price decreased by The Goldman Sachs Group from $37.00 to $9.00 in a report released on Tuesday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Chardan Capital decreased their price objective on uniQure from $53.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday. Stifel Nicolaus set a $14.00 target price on uniQure in a report on Monday. Wells Fargo & Company reiterated an “equal weight” rating and set a $15.00 price target (down from $60.00) on shares of uniQure in a research report on Tuesday. Finally, William Blair restated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $34.33.

uniQure Price Performance

Shares of NASDAQ QURE opened at $9.03 on Tuesday. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The business’s 50 day moving average price is $22.86 and its 200 day moving average price is $29.72. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market cap of $562.48 million, a P/E ratio of -2.62 and a beta of 0.73.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 230.98%. On average, sell-side analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 12,378 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $295,339.08. Following the completion of the sale, the chief executive officer directly owned 639,076 shares in the company, valued at $15,248,353.36. The trade was a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 6,217 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the transaction, the chief financial officer directly owned 211,513 shares of the company’s stock, valued at approximately $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 50,598 shares of company stock valued at $1,248,588 in the last three months. 4.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new position in shares of uniQure during the 3rd quarter worth about $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System lifted its position in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat the EPS consensus (reported loss narrower than expected) and revenue slightly exceeded estimates — provides near‑term financial relief but did not offset regulatory concerns. Q4 press release
• Positive Sentiment: Some analysts remain constructive after repricing: Chardan retained a “buy” rating (lowered PT) and Wells Fargo kept an “equal weight” stance, which could support buyer interest if worries ease. Analyst notes
• Neutral Sentiment: uniQure says it held a Type A meeting with the FDA, is evaluating Phase‑III plans for AMT‑130 and intends to request a follow‑up Type B meeting in Q2 — this signals a defined regulatory path but will likely take time and resources. Company update
• Neutral Sentiment: Corporate disclosure flagged a governance risk tied to a 2026 shift to the Dutch “large company” regime — a longer‑term structural governance change that bears monitoring but is not an immediate earnings driver. TipRanks note
• Negative Sentiment: Regulatory blow: the FDA told uniQure its early‑stage AMT‑130 data are insufficient for a marketing application and has recommended a randomized, sham‑controlled Phase III study — a materially more onerous and time‑consuming path that triggered the sharp market selloff. Reuters: FDA tells UniQure
• Negative Sentiment: Analysts slashed price targets and ratings after the FDA decision (Goldman lowered its PT to $9 and moved to neutral; Cantor, RBC, Mizuho and others also cut PTs or ratings) — analyst repricing removes supporting buy‑side momentum and amplifies downside risk. Analyst coverage changes
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs for securities class actions tied to the company’s disclosures during a defined class period — increased legal risk, potential settlements or litigation costs add uncertainty for shareholders. Rosen Law Firm notice
• Negative Sentiment: Market reaction: heavy volume and steep price declines since the FDA announcement reflect rapid repricing of AMT‑130’s value and higher execution risk for the company’s lead gene‑therapy program. Bloomberg coverage

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.